We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Early-Stage Alzheimer’s Disease: New Therapies for Mild Cognitive Impairment
Sharon Cohen, MD, FRCPC
Richard S. Isaacson, MD
Marwan Noel Sabbagh, MD, FAAN, CCRI
Evidence-Based Discussion of the New and Emerging DMT Treatment Strategies for MCI
Professional Recommendations of Clinically Validated Tools Used to Diagnose MCI in AD
Evolving Treatment Paradigms For Mild Cognitive Impairment and Dementia: How New DMTs Will Fit Into Clinical Practice
Novel and Emerging Disease Modifying Therapies for Mild Cognitive Impairment Due to AD: Efficacy and Safety of New DMTs for MCI
New Data on the Pathophysiology of MCI and Dementia
Disparities and Inequities in the Diagnosis and Care of Vulnerable Patient Populations
Expert Opinion on How the New DMTs Fit into Everyday Clinical Practice
Challenges in Recognizing and Diagnosing MCI in AD Earlier
Negative Impacts of Excessive Daytime Sleepiness Due to Obstructive Sleep Apnea
Neomi Shah, MD, MPH, MSc
Obstructive Sleep Apnea: Emerging Therapies for Excessive Daytime Sleepiness
Atul Malhotra, MD
Christina Finch, MD
How to Identify Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
Case Study: Adjusting STOP-BANG Screening Criteria for Minority Ethnic Groups
Experts Debate: How Novel Excessive Daytime Sleepiness Treatments Fit Into Clinical Practice for Obstructive Sleep Apnea
New Treatments for Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education